Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barre Syndrome in Korea: A Nationwide Multicenter Study by 理쒖쁺泥�
94  Copyright © 2014 Korean Neurological Association  
Print ISSN 1738-6586 / On-line ISSN 2005-5013
http://dx.doi.org/10.3988/jcn.2014.10.2.94
ORIGINAL ARTICLE
J Clin Neurol 2014;10(2):94-100
Prevalence of Anti-Ganglioside Antibodies and Their Clinical  
Correlates with Guillain-Barré Syndrome in Korea:  
A Nationwide Multicenter Study
Jong Kuk Kim,a Jong Seok Bae,b Dae-Seong Kim,c Susumu Kusunoki,d Jong Eun Kim,e Ji Soo Kim,f  
Young-Eun Park,c Ki-Jong Park,g Hyun Seok Song,h Sun Young Kim,i Jeong-Geun Lim,j Nam-Hee Kim,k  
Bum Chun Suh,l Tai-Seung Nam,m Min Su Park,n Young-Chul Choi,o Eun Hee Sohn,p Sang-Jun Na,q  
So Young Huh,r Ohyun Kwon,s Su-Yun Lee,a Sung-Hoon Lee,b Sun-Young Oh,t Seong-Hae Jeong,p  
Tae-Kyeong Lee,u Dong Uk Kimv
aDepartment of Neurology, College of Medicine, Dong-A University, Busan, Korea, bDepartment of Neurology, College of Medicine,  
Hallym University, Seoul, Korea, cDepartment of Neurology, School of Medicine, Pusan National University, Busan, Korea, 
dDepartment of Neurology, School of Medicine, Kinki University, Osaka, Japan, eDepartment of Industrial and Occupational Medicine, 
Pusan National University School of Medicine, Busan, Korea, fDepartment of Neurology, College of Medicine, Seoul National University, 
Seoul, Korea, gDepartment of Neurology, School of Medicine, Gyeongsang National University, Jinju, Korea, hDepartment of Neurology, 
School of Medicine, Kyungpook National University, Daegu, Korea, iDepartment of Neurology, College of Medicine, University of Ulsan, 
Ulsan, Korea, jDepartment of Neurology, School of Medicine, Keimyung University, Daegu, Korea, kDepartment of Neurology,  
College of Medicine, Dongguk University, Seoul, Korea, lDepartment of Neurology, School of Medicine, Sungkyunkwan University, Seoul, Korea, 
mDepartment of Neurology, Chonnam National University Medical School, Gwangju, Korea, nDepartment of Neurology,  
School of Medicine, Yeungnam University, Daegu, Korea, oDepartment of Neurology, College of Medicine, Yonsei University, Seoul, Korea, 
pDepartment of Neurology, School of Medicine, Chungnam National University, Daejeon, Korea, qDepartment of Neurology,  
College of Medicine, Konyang University, Daejeon, Korea, rDepartment of Neurology, College of Medicine, Kosin University, Busan, Korea, 
sDepartment of Neurology, School of Medicine, Eulji University, Seoul, Korea, tDepartment of Neurology, School of Medicine,  
Chonbuk National University, Jeonju, Korea, uDepartment of Neurology, College of Medicine, Soonchunhyang University, Seoul, Korea, 
vDepartment of Neurology, School of Medicine, Chosun University, Gwangju, Korea
Received July 20, 2013
Revised October 5, 2013
Accepted October 16, 2013
Correspondence
Jong Seok Bae, MD, PhD
Department of Neurology,  
Kangdong Sacred Heart Hospital,  
College of Medicine, 
Hallym University,  
150 Seongan-ro, Gangdong-gu,  
Seoul 134-701, Korea
Tel    +82-2-2224-2854
Fax   +82-2-2224-2114
E-mail    jsb_res@hotmail.co.kr
Background and PurposezzNo previous studies have investigated the relationship between 
various anti-ganglioside antibodies and the clinical characteristics of Guillain-Barré syndrome 
(GBS) in Korea. The aim of this study was to determine the prevalence and types of anti-gangli-
oside antibodies in Korean GBS patients, and to identify their clinical significance.
MethodszzSerum was collected from patients during the acute phase of GBS at 20 university-
based hospitals in Korea. The clinical and laboratory findings were reviewed and compared with 
the detected types of anti-ganglioside antibody.
ResultszzAmong 119 patients, 60 were positive for immunoglobulin G (IgG) or immunoglob-
ulin M antibodies against any type of ganglioside (50%). The most frequent type was IgG anti-
GM1 antibody (47%), followed by IgG anti-GT1a (38%), IgG anti-GD1a (25%), and IgG anti-
GQ1b (8%) antibodies. Anti-GM1-antibody positivity was strongly correlated with the presence 
of preceding gastrointestinal infection, absence of sensory symptoms or signs, and absence of 
cranial nerve involvement. Patients with anti-GD1a antibody were younger, predominantly 
male, and had more facial nerve involvement than the antibody-negative group. Anti-GT1a-an-
tibody positivity was more frequently associated with bulbar weakness and was highly associ-
ated with ophthalmoplegia when coupled with the coexisting anti-GQ1b antibody. Despite the 
presence of clinical features of acute motor axonal neuropathy (AMAN), 68% of anti-GM1- or 
anti-GD1a-antibody-positive cases of GBS were diagnosed with acute inflammatory demyelin-
ating polyradiculoneuropathy (AIDP) by a single electrophysiological study.
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Introduction
Guillain-Barré syndrome (GBS) is an acute polyradiculoneu-
ropathy characterized by ascending muscle weakness and are-
flexia.1 Immune-mediated mechanisms are thought to be re-
sponsible for the pathogenesis of GBS. Although this condition 
has been the subject of a considerable amount of research over 
several decades, no clear pathophysiological target of human 
acute inflammatory demyelinating polyradiculoneuropathy 
(AIDP) has been found. In contrast, a direct causative relation-
ship has been found between acute motor axonal neuropathy 
(AMAN) and anti-ganglioside antibodies.2 Recent studies 
have demonstrated the existence of an association between 
gangliosides and autoimmune mechanisms. Evidence for this 
association has been gleaned from experimental studies demon-
strating the cross-reactivity of autoantibodies induced by 
ganglioside antigens against the axolemma of the host’s periph-
eral nerves.3,4 Many other studies have demonstrated that this 
molecular mimicry hypothesis is most consistent with Cam-
pylobacter jejuni infection.5
Several of the anti-ganglioside antibodies, including anti-
GM1, GM1b, GD1a, and N-acetylgalactosaminyl GD1a (Gal-
NAc-GD1a), are common in GBS sufferers from Asian coun-
tries and are representative markers of AMAN.5 It was recently 
revealed that these antibodies are important in determining the 
electrophysiological characteristics of GBS.6 Uncini et al.7 
found that some anti-ganglioside-antibody-positive cases that 
were initially classified as demyelinating or undetermined 
types following nerve conduction studies (NCSs) were ulti-
mately revealed to be axonal type on follow-up NCSs. Thus, 
an accurate classification of GBS subtypes requires serial 
NCSs. Moreover, this study7 demonstrated that the assay of 
anti-ganglioside antibodies can be a useful tool for determin-
ing the type of GBS at an early stage in the disease.
It is known that diverse clinical features of variant GBS 
cases can be attributed to each anti-ganglioside antibody.8-11 
For example, the anti-GT1a antibody is the key factor under-
lying bulbar and brachial palsies in GBS,9,12,13 and the anti-
GQ1b antibody is known to be a specific primary factor un-
derlying Miller Fisher syndrome (MFS), and can explain the 
oculomotor palsy and other cranial-nerve involvement found 
in GBS.14-16 Therefore, investigation of the anti-ganglioside 
antibodies provides an opportunity to improve the under-
standing of diverse manifestations of GBS and the related 
pathomechanisms.5,17 The aim of this study was thus to deter-
mine the frequency of anti-ganglioside antibodies in GBS and 
related clinical syndromes in a Korean population. In addition, 
the efficacy of conventional electrophysiological study for the 
diagnosis of AMAN in Koreans was determined.
Methods
Study design
Data were collected from GBS patients admitted to 20 uni-
versity-based hospitals in Korea. Among the 574 patients who 
expressed a desire to participate in the anti-ganglioside anti-
body study for acute peripheral neuropathies during the peri-
od of January 2008 to December 2009, 119 clinically compat-
ible GBS cases met the defined criteria and were selected as 
study subjects.1 Patients with MFS, Bickerstaff’s brainstem 
encephalitis (BBE), or other atypical variants such as a pha-
ryngeal-cervical-brachial (PCB) variant were not included in 
this study. During the study period, 38, 3, and 5 patients with 
anti-GQ1b antibody syndrome including classical MFS, BBE, 
and PCB with positive anti-GT1a antibody, respectively, 
were encountered. Data regarding the patients’ age, sex, type 
of preceding infection, presenting symptoms, neurological 
signs, treatment, and cerebrospinal fluid (CSF) findings were 
analyzed. The GBS disability score, as defined by Hughes et 
al.,18 was used in this study. Neurological signs were further 
classified according to the presence of cranial nerve involve-
ments such as oculomotor palsy, facial nerve palsy or oropha-
ryngeal weakness, respiratory disturbances requiring mechani-
cal ventilation, and objective sensory changes.
Anti-ganglioside antibody study
Serum samples were obtained from patients during the acute 
stage within 2 weeks of symptom onset. An enzyme-linked 
immunosorbent assay (ELISA) was used to detect the various 
types of anti-ganglioside antibodies, including immunoglob-
ulin G (IgG) and immunoglobulin M (IgM) antibodies against 
the gangliosides GM1, GM2, GM3, GD1a, GD1b, GD3, GT1a, 
ConclusionszzAnti-ganglioside antibodies were frequently found in the serum of Korean 
GBS patients, and each antibody was correlated strongly with the various clinical manifesta-
tions. Nevertheless, without an anti-ganglioside antibody assay, in Korea AMAN is frequently 
misdiagnosed as AIDP by single electrophysiological studies. J Clin Neurol 2014;10(2):94-100
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GT1b, and GQ1b, as described previously.11 Although they 
are not true gangliosides, testing was also performed for ga-
lactocerebroside and asialo-GM1. The presence and types of 
anti-ganglioside antibodies were analyzed by researchers who 
were blinded to the patients’ presenting neurological signs 
and electrophysiological classifications.
Electrophysiological classification
Electrophysiological evaluations were made based on the 
neurologists’ decisions to choose primary axonal form or de-
myelination when they requested ELISA for anti-ganglioside 
antibodies.19,20 An initial NCS was performed within 2 weeks 
of the onset of motor weakness, as described earlier.21 The me-
dian, ulnar, peroneal, and tibial nerves were selected for mo-
tor NCSs, and the median, ulnar, and sural nerves were select-
ed for sensory NCSs. F-wave evaluations were also conducted 
from all selected motor nerves. Accordingly, all patients were 
classified as having primary demyelinating, primary axonal, 
or unclassified GBS.19,20 Findings of primary axonal or prima-
ry demyelinating GBS were further classified as either pure 
motor or sensorimotor types using electrophysiological pa-
rameters. All findings were interpreted by each referring neu-
rology specialist who was blinded to the anti-ganglioside an-
tibody results.
Standard protocol and patient consent
The data for all patients were compiled using a standardized 
protocol that was reviewed and approved by the ethical com-
mittee at the Dong-A University Medical Center, Busan, Ko-
rea. Furthermore, informed consent to participate was ob-
tained from all patients or their caregivers.
Statistical analysis
Statistical analysis was performed using Statistical Analysis 
System (SAS) version 9.0 (SAS Institute Inc., Cary, NC, USA). 
With respect to the clinical features of the GBS patients, dif-
ferences in proportions between groups were tested using the 
chi-square test or Fisher’s exact test, and differences in medi-
ans were tested using the Mann-Whitney U test. Two-sided 
tests were used throughout, and the level of statistical signifi-
cance was set at p<0.05.
Results
Demographics of patients with anti-ganglioside 
antibodies
In total, 119 GBS patients (diagnosed using the relevant cri-
teria) were analyzed, of which 79 were men and 40 were 
women. The age at onset ranged from 15 to 80 years (median 
55.4 years). Seventy-three patients (61%) had a history of pre-
ceding infection, and 60 (50%) were positive for IgG or IgM 
antibodies against the various types of gangliosides. Of those 
60, 58 were positive for IgG-type anti-ganglioside antibodies 
and 8 were positive for IgM antibodies; thus, 6 of the IgM-
positive cases were simultaneously positive for IgG-type anti-
ganglioside antibodies.
Analysis of the clinical findings according to the presence 
of any type of anti-ganglioside antibody revealed that the an-
tibody-positive group had a higher ratio of men, a younger age 
at onset, more frequent preceding gastrointestinal events with 
a short interval from infection to motor weakness, less fre-
quent sensory symptoms or signs, and a lower level of CSF 
proteins (Table 1). Immunomodulating treatment was per-
formed in 87% and 83% of patients from each antibody-pos-
itive and -negative group during the acute stage. The modality 
was intravenous human immunoglobulin in all treated pa-
tients, regardless of additional plasmapheresis. Motor disabili-
ty scores on admission, and at 4 weeks and 3 months thereaf-
Table 1. Comparison of the clinical characteristics between the anti-ganglioside-antibody-positive and -negative groups
Positive (n=60) Negative (n=59) p
Proportion of men 45/60 (75%) 34/59 (58%) 0.045
Age (years) Median, 47.8
(range, 15–81)
Median, 54.7
(range, 16–82)
0.030
Preceding infection 49 (82%) 33 (56%) 0.002
Gastrointestinal infection vs. upper-respiratory-tract infection 23:19 5:26 0.001
Interval from infection to symptom onset (days) 6.3±4.5 9.8±6.3 0.025
Objective sensory signs 8 (13%) 34 (58%) 0.001
Respiratory disturbance requiring mechanical ventilation 16 (27%) 12 (20%) 0.416
Cranial nerve abnormalities 29 (48%) 33 (56%) 0.352
Cerebrospinal fluid protein (mg/dL) 45.5±25.6 86.9±74.9 0.001
Motor disability score on admission 2.6±1.1 2.9±1.1 0.091
Motor disability score at 4 weeks 3.2±1.3 3.4±1.2 0.316
Motor disability score at 3 months 1.6±1.5 1.4±1.2 0.386
Except where specified otherwise, the data are n (%) or mean±SD values.
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ter did not differ significantly between the groups (p=0.091, 
0.316, and 0.386, respectively).
Clinical significance of each anti-ganglioside 
antibody
Among the patients who were anti-ganglioside-antibody posi-
tive, the most frequent was IgG anti-GM1 antibody (28 pa-
tients, 47%), followed by IgG anti-GT1a (23 patients, 38%), 
and anti-GD1a (15 patients, 25%) antibodies (including over-
lapping cases) (Fig. 1). Anti-GQ1b antibodies were also found 
in ten patients, all of whom were also positive for anti-GT1a 
antibody.
Anti-GM1-antibody-positive cases
Anti-GM1-antibody positivity was strongly correlated with 
the presence of preceding gastrointestinal infection (61%, 
p=0.001), negative sensory signs (14%, p<0.001), absence of 
cranial nerve involvement (25%, p=0.006), and a lower CSF 
protein level (p=0.004) compared with the antibody-negative 
group. Motor function score and the frequency of respiratory 
disturbance requiring mechanical ventilation did not differ 
significantly from the antibody-negative group.
Anti-GD1a-antibody-positive cases
Patients with anti-GD1a antibody exhibited a similar pattern 
to the anti-GM1-positive group, with a younger onset age (me-
dian 41.3 years, range 25–72 years; p=0.003), frequent occur-
rences in men (86%, p=0.037), and fewer sensory signs (0%, 
p<0.001) compared with the antibody-negative group. Anti-
GD1a-antibody positivity was frequently associated with fa-
cial diplegia, regardless of other accompanying antibodies or 
the absence of anti-ganglioside antibodies (10/15, 66%; p= 
0.066).
Overlap syndrome of cranial neuropathy associated with 
anti-GT1a with/without anti-GQ1b antibody
In addition to the typical anti-GM1 antibody related to AMAN 
pattern, the present results revealed that a large proportion of 
the patients had anti-GT1a or anti-GQ1b positivity. The IgG 
anti-GT1a antibody was frequently associated with cranial 
nerve abnormality (17/23, 74%; p=0.001) (Fig. 2). Compared 
with the IgG anti-GM1-antibody-positive group, presence of 
the anti-GT1a antibody was strongly associated with oropha-
ryngeal weakness or other lower cranial neuropathies (16/23, 
70% vs. 4/28, 14%; p<0.001). Although ophthalmoplegia ap-
peared to occur more frequently in the anti-GT1a-positive 
group compared with the anti-GM1-positive group (8/23, 
35% vs. 3/27, 11%), the difference was not significant (p= 
0.084). The simultaneous presence of the IgG anti-GQ1b an-
tibody was more common in the anti-GT1a-positive group 
than in the anti-GM1-positive group (10/23, 44% vs. 1/28, 4%; 
p=0.001). Extraocular muscle weakness was strongly corre-
lated with the co-occurrence of anti-GQ1b antibody in the 
anti-GT1a-positive group (6/10 anti-GQ1b-antibody-positive 
cases) (Fig. 2). IgG anti-GD1a-antibody positivity was more 
Fig. 1. Various kinds of anti-ganglioside antibodies were detected in Korean patients with Guillain-Barré syndrome. The most frequent type 
was immunoglobulin G anti-GM1 antibody, followed by IgG anti-GT1a antibody (immunoglobulin M-type anti-ganglioside antibodies were 
not considered in this figure, and all patient numbers were calculated with overlapping). GA1: asialo-GM1, GalC: galactocerebroside.
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Fig. 2. Patients who were IgG anti-GT1a-antibody positive fre-
quently exhibited cranial nerve signs (n=17, 74%; not shown in the 
figure). The most prominent sign was oropharyngeal weakness 
(n=16, 70%). Ophthalmoplegia was also frequent, and was strong-
ly correlated with oropharyngeal weakness and coexisting IgG 
anti-GQ1b-antibody positivity. However, four of the ten IgG anti-
GQ1b-antibody-positive cases had no oculomotor palsy during the 
disease course. The numerals inside circles represent the numbers 
for each condition.
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common in the anti-GT1a-antibody-positive group than in 
the anti-GM1-antibody-positive group (9/23, 39% vs. 2/28, 
7%; p=0.014). Only four cases were simultaneously positive 
for anti-GM1 and anti-GT1a antibodies, among whom one 
was also positive for anti-GD1a antibody and another was also 
positive for anti-GQ1b antibody.
Cases positive for other types of antibody
There was positivity for other minor antibodies against gangli-
osides GT1b, GD1b, asialo-GM1, GD3, and galactocerebro-
side in nine, four, three, one, and one case, respectively, re-
gardless of other coexisting anti-ganglioside antibodies. 
However, there was no clinical significance for these cases. 
None of the cases were positive for either anti-GM2 or anti-
GM3 antibodies. There were no isolated IgG anti-GQ1b-an-
tibody-positive cases.
Correlation between electrophysiological and 
anti-ganglioside antibody findings
Anti-GM1 and anti-GD1a antibodies are known to be axonal 
markers, but the patients who were positive for these antibod-
ies did not exhibit significant differences in terms of the pro-
portion of primary axonal pattern at initial NCS in compari-
son to those who were negative for those antibodies (27% vs. 
20%; mean, 7.3 days from symptom onset; p=0.693) (Table 2). 
All of the diagnoses were made by neurology specialists on 
the basis of a single, conventional NCS. Twenty-eight of the 
41 patients who were positive for IgG anti-GM1 or anti-GD1a 
antibodies were classified as having primary demyelination 
at the initial NCS; 21 cases exhibited a pure motor presenta-
tion and only 7 patients displayed typical sensorimotor demy-
elinating polyneuropathy. Conversely, 37 of the 41 antibody-
negative patients who were classified as having primary 
demyelination exhibited a classical sensorimotor polyneu-
ropathy pattern (Table 2).
Discussion
This is the first investigation of anti-ganglioside antibodies 
and their clinical significance in Korean GBS. The findings 
show that half of the included Korean GBS patients were 
positive for various types of anti-ganglioside antibody. The 
high frequency of anti-ganglioside antibodies revealed herein 
suggests that they are a continuum of the results obtained in 
China and Japan.5,20,22 Thus, compared to western countries, 
the proportion of AMAN seems to be higher in Korea, and 
similar to those reported in eastern Asian countries. The clin-
ical findings of the antibody-positive group were clearly dif-
ferent from those of the antibody-negative group, although 
the classes of antibodies detected were diverse. The clinical 
findings of the antibody-positive group included male pre-
dominance, frequent preceding gastrointestinal infection, 
short interval from infection to motor weakness, negative 
sensory signs, and lower CSF levels of protein. These find-
ings were also evident when the anti-GM1- or anti-GD1a-pos-
itive group was compared with the antibody-negative group. 
However, a considerable number of the patients who were 
anti-ganglioside-antibody positive were classified electro-
physiologically as having demyelinating GBS. Therefore, the 
present findings also reaffirm the previous suggestion that 
using a single electrophysiological test can result in the erro-
neous misdiagnosis of AMAN as AIDP.7 Overall, it can be as-
sumed that regardless of the electrophysiological classifica-
tion, half of all Korean GBS patients exhibit the axonal type.
Previous studies have revealed that anti-ganglioside-anti-
body-positive cases, such as anti-GM1- or anti-GD1a-posi-
tive, exhibited different clinical manifestations compared to 
those with antibody-negative GBS.6,23,24 This finding is attrib-
utable to differences in the pathomechanisms of AMAN and 
AIDP. Although the underlying pathophysiology of AIDP is 
obscure, damage to the myelin sheath of the sensory and mo-
tor nerves by cellular immunity was suggested to occur in 
AIDP.2 In contrast, several recent studies have provided im-
portant information regarding the immunological mecha-
nisms underlying AMAN pathology. According to these stud-
ies, the core factor is destruction of the paranodal axolemma 
induced by humoral autoimmunity, including anti-ganglio-
side antibodies and the compliment system.25-27
One particularly notable finding of the present study was 
the high frequency of IgG-type anti-GT1a-antibody positivity 
in Korean GBS. Originally, the anti-GT1a antibody was de-
termined to be a specific marker of the PCB variant of GBS.28 
This antibody is closely related to the ophthalmoplegia, fa-
cial diplegia, or bulbar palsy.9,29 Since the MFS and PCB vari-
ants of GBS were excluded from the present study, the posi-
tivity of this antibody in GBS had particular significance 
Table 2. Comparison of the electrophysiological classification between the anti-GM1- or anti-GD1a-antibody-positive and -negative groups
Group
Classification by initial nerve conduction study at a mean of 7.3 days
Primary axonal type
Primary demyelinating type
Unclassified
Pure motor Sensorimotor
Antibody positivity (n=41) 11 (27%) 21 (51%) 7 (17%) 2 (45%)
Antibody negativity (n=59) 12 (20%) 4 (7%) 37 (63%) 8 (14%)
The data are n (%) values.
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with respect to various clinical manifestations. The presence 
of anti-GT1a antibody resulted in a high proportion of patients 
with bulbar weakness compared with the anti-GM1-positive 
group. Anti-GQ1b-antibody positivity within the anti-GT1a 
group may be responsible for the coexisting ophthalmople-
gia; this finding can be explained by cross-reaction with gan-
gliosides of a similar structure.9 Although we do not know the 
difference from typical MFS cases, one interesting point is 
that anti-GQ1b-antibody positivity in this series does not ap-
pear to be associated with ataxia (only three cases).
Among the different types of cranial neuropathy, facial di-
plegia was found in 40 patients. The frequency of facial weak-
ness did not differ significantly between the antibody-posi-
tive and -negative groups. However, in the antibody-positive 
group, facial diplegia was strongly associated with the pres-
ence of anti-GD1a antibody in this study. Although facial di-
plegia is a common manifestation of GBS, it can be an isolat-
ed sign or a presenting manifestation in some GBS patients.30 
Some authors have suggested that prominent facial diplegia 
is correlated with accompanying anti-GD1a-antibody posi-
tivity, although GD1a ganglioside was originally found mainly 
in the ventral horn and motor fibers of the cauda equina.31-33
Electrophysiological evaluation is an important part of un-
derstanding the pathomechanism underlying GBS. It is strong-
ly correlated with the presence of anti-ganglioside antibod-
ies, and especially that of GM1, GM1b, GD1a, and GalNAc-
GD1a as axonal markers.6 The results of NCSs were compared 
between anti-GM1- or anti-GD1a-antibody-positive and -neg-
ative groups. Unexpectedly, the prevalence of either the axo-
nal or demyelinating subtypes did not differ significantly be-
tween these two groups at the initial evaluation according to 
the NCS criteria.19,20 Previous studies have shown that some 
AMAN patients exhibit transient conduction blocks in the 
intermediate and distal nerve segments, mimicking demyelin-
ation–a condition known as reversible conduction failure.7,34 
This rapidly reversible conduction block, which resolves 
within days to a few weeks, is found frequently in AMAN pa-
tients. This time course suggests functional or microstructur-
al changes at the nodes of Ranvier, rather than segmental de-
myelination and remyelination; thus, serial NCS is required to 
confirm the fate of conduction block or axonal degeneration.6,7
The interpretation of the electrophysiological results is lim-
ited by only one NCS being conducted in most cases, with no 
long-term follow up. Although it was not possible to analyze 
long-term follow-up results, it was noted that the pattern of in-
volvement in the antibody-positive group appeared to be quite 
different from that in the antibody-negative group. A high pro-
portion of anti-ganglioside-antibody-positive GBS patients 
exhibited a pure motor type, while most of the antibody-neg-
ative GBS patients had typical sensorimotor involvement. It 
is thus possible that some of the antibody-positive GBS pa-
tients could be classified as exhibiting demyelination accord-
ing to the initial, single NCS criteria, such as prolonged termi-
nal latency or conduction block.6,35,36 Unfortunately, we were 
unable to analyze the detailed factors contributing to the clas-
sification of each case in this study; however, we speculate 
that the presence of anti-ganglioside antibody and a pure 
motor presentation on NCS could reflect a different patho-
physiological background from that of classical sensorimotor 
GBS without anti-ganglioside antibodies. In this sense, stud-
ies of anti-ganglioside antibodies are important to understand-
ing the various subtypes and manifestations of GBS.
The prognosis did not differ significantly between the anti-
ganglioside-antibody-positive and -negative groups. It could 
be speculated that this is because Korean GBS patients have 
the opportunity to be treated with intravenous immunoglobu-
lin in the acute stage of the disease, with the support of the na-
tional insurance system. Early treatment could halt the revers-
ible conduction failure and prevent axonal degeneration even 
in AMAN patients. However, this study was subject to impor-
tant limitations, such as the follow-up period being too short 
(3 months) and the interpretation of the electrophysiological 
characteristics being limited. However, it was found that a high 
proportion of Korean GBS patients expressed a variety of anti-
ganglioside antibodies, which may explain the observed di-
verse clinical characteristics.
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